|DL-Homocysteine 目录号 GC30684|
Sample solution is provided at 25 µL, 10mM.
|Cas No.||454-29-5||SDF||Download SDF|
|溶解度||H2O : 75 mg/mL (554.77 mM)||储存条件||Store at -20°C|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.|
|Shipping Condition||Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
DL-Homocysteine is a weak neurotoxin, and can affect the production of kynurenic acid in the brain.
DL-Homocysteine (0.1-0.5 mM) significantly enhances kynurenic acid (KYNA) production in rat cortical slices, and diministes the production of at 3.0, 5.0, and 10.0 mM, with the estimated IC50 of 6.4 (5.5-7.5) mM. DL-Homocysteine dose-dependently inhibits kynurenine aminotransferases I (KATI) activity at concentrations ≥0.2 mM, with an IC50 of 0.566 (0.442-0.724) mM, and the activity of KAT II with IC50 value of 8.046 (5.804-11.154) mM.
DL-Homocysteine (1.3 mmol/kg, i.p.) increases KYNA content (pmol/g tissue) from 8.47 ± 1.57 to 13.04 ± 2.86 and 11.4 ± 1.72 in cortex, and from 4.11 ± 1.54 to 10.02 ± 3.08 in rat hippocampus.
. DL-Homocysteine, et al. Dual effect of DL-homocysteine and S-adenosylhomocysteine on brain synthesis of the glutamate receptor antagonist, kynurenic acid. J Neurosci Res. 2005 Feb 1;79(3):375-82.